Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review, Expert Opin Drug Saf, vol.9, pp.683-97, 2010. ,
Second-generation antipsychotic long-acting injections: systematic review, Br J Psychiatry, vol.52, pp.29-36, 2009. ,
Risperidone long-acting injection: a review of its long term safety and efficacy, Neuropsychiatr Dis Treat, vol.4, pp.919-946, 2008. ,
Remission in schizophrenia: proposed criteria and rationale for consensus, Am J Psychiatry, vol.162, pp.441-450, 2005. ,
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection, Schizophrenia Res, vol.77, pp.215-242, 2005. ,
Direct transition to long-acting risperidone -analysis of long-term efficacy, J Psychopharmacol, vol.19, pp.15-21, 2005. ,
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months, Intl J Clin Pharmacol Ther, vol.46, pp.14-22, 2008. ,
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies, Intl Clin Psychopharmacol, vol.20, pp.121-151, 2005. ,
Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study, Schizophrenia Res, vol.133, pp.42-48, 2011. ,
Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application, J Clin Psychiatry, vol.75, pp.8-14, 2014. ,
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable, Clin Drug Invest, vol.32, pp.267-79, 2012. ,
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome, Human Psychopharmacol Clin Expl, vol.25, pp.243-52, 2010. ,
Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE), Acta Neuropsychiatrica, vol.25, pp.297-306, 2013. ,
Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone, Encephale, vol.34, pp.170-178, 2008. ,
Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment, Eur Psychiatry, vol.25, pp.220-229, 2010. ,
Traitement de l'information en matière de recherche dans le domaine de la santé, Med Sci (Paris), vol.25, pp.93-101, 2009. ,
, des études, de l'évaluation et des statistiques, vol.88, p.1, 2005.
Functional outcome in bipolar disorder: the role of clinical and cognitive factors, Bipolar Disorders, vol.9, pp.103-116, 2007. ,
Remission of positive symptoms according to the "remission in Schizophrenia Working Group" criteria: A longitudinal study of cognitive functioning, Eur Psychiatry, vol.28, pp.282-289, 2013. ,
Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances, Schizophrenia Res: Cognition, vol.1, pp.187-92, 2014. ,
The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia, Schizophrenia Res, vol.143, pp.107-122, 2013. ,
Remission criteria and functional outcome in schizophrenia patients. A longitudinal study, Schizophrenia Res, vol.153, issue.1, pp.166-173, 2014. ,
Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders, Psychiatry Res, vol.210, pp.739-783, 2013. ,
Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia, Progress NeuroPsychopharmacol Biological Psychiatry, vol.33, pp.373-382, 2009. ,